Complicated Urinary Tract Infection: Clinical Trials

8 trials for Complicated Urinary Tract Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 28Completed 5, Active not recruiting 1, Recruiting 1, Unknown 1

Follow Complicated Urinary Tract Infection: new trials by email Literature Review of Complicated Urinary Tract Infection trials Research Report on Complicated Urinary Tract Infection

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Meropenem-Vaborbactam, Antibiotics - Acute Pyelonephritis, Complicated Urinary Tract Infection
Phase 2Active not recruitingRempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)662025-06-032026-09-10
A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
cefepime and enmetazobactam combination - Complicated Urinary Tract Infection
Phase 2RecruitingOrchid Pharma Europe GmbH402023-09-112026-08-20
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
Meropenem- FL058, Piperacillin -tazobactam, Saline - Complicated Urinary Tract Infection, Acute Pyelonephritis
Phase 2UnknownQilu Pharmaceutical Co., Ltd.1502021-10-082021-09-29
MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
Ceftolozane/Tazobactam, Meropenem - Complicated Urinary Tract Infection, Pyelonephritis
Phase 2CompletedMerck Sharp & Dohme LLC1342018-04-262023-05-06
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
Sulbactam-ETX2514, Placebo, Imipenem-cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis
Phase 2CompletedEntasis Therapeutics802018-01-172020-01-22
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
levofloxacin, plazomicin, placebo - Complicated Urinary Tract Infection, Acute Pyelonephritis
Phase 2CompletedAchaogen, Inc.1452010-07-132018-08-22
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
CXA-101, Ceftazidime - Complicated Urinary Tract Infection
Phase 2CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1292009-06-302018-10-18
Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
NXL104/ceftazidime, Imipenem/Cilastatin - Complicated Urinary Tract Infection
Phase 2CompletedPfizer1372008-11-012018-05-25

Narrower conditions

Pyelonephritis (3)  ·  Urinary Tract Infections (1)

Broader conditions

Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Kidney Diseases (3)  ·  Male Urogenital Diseases (3)  ·  Nephritis (3)  ·  Nephritis, Interstitial (3)  ·  Pyelitis (3)  ·  Urogenital Diseases (3)  ·  Urologic Diseases (3)  ·  Infections (1)

Interventions

Ceftazidime (2)  ·  Cilastatin, Imipenem Drug Combination (2)  ·  Anti-Bacterial Agents (1)  ·  Cefepime (1)  ·  Levofloxacin (1)  ·  Meropenem (1)  ·  Piperacillin, Tazobactam Drug Combination (1)  ·  Sodium Chloride (1)  ·  avibactam (1)  ·  cefepime, enmetazobactam drug combination (1)  ·  ceftolozane (1)  ·  ceftolozane, tazobactam drug combination (1)  ·  meropenem and vaborbactam (1)  ·  plazomicin (1)

Sponsors

Achaogen, Inc. (1)  ·  Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Entasis Therapeutics (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Orchid Pharma Europe GmbH (1)  ·  Pfizer (1)  ·  Qilu Pharmaceutical Co., Ltd. (1)  ·  Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) (1)

Countries

Poland (4)  ·  United States (4)  ·  Bulgaria (2)  ·  Greece (2)  ·  Hungary (2)  ·  Croatia (1)  ·  Czechia (1)  ·  France (1)  ·  Georgia (1)  ·  Germany (1)  ·  Jordan (1)  ·  Lebanon (1)  ·  Mexico (1)  ·  Romania (1)  ·  Russia (1)

Top investigators

Ahmad Haidar, MD (1)  ·  Anibal Calmaggi, MD (1)  ·  Carole A Sable, MD (1)  ·  Florian Wagenlehner, MD (1)  ·  Huang Haihui, Professor (1)  ·  Ryszard Gellert, MD (1)

Results publications

PMID 23145859, PMID 31843995, PMID 36689671

NIH funding

2016 (1)